Halia Therapeutics
Salt Lake City, UT · Biotechnology · 27 employees
Halia is a clinical-stage biopharmaceutical company discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.
Funding history
- Seed — $337K — Jul 2025
- Series C — $30.0M — Jan 2024
- Venture - Series Unknown — $12.2M — Dec 2022
- Venture - Series Unknown — $5.0M — Feb 2021
- Venture - Series Unknown — $6.3M — Oct 2020
Recent signals
- May 12, 2026: Halia Therapeutics Appoints Han Myint as Chief Medical Officer
- Oct 06, 2025: Halia Therapeutics Appoints Paul Jones as Chief Strategy Officer & GM
- Jul 16, 2025: Raised $337K in Seed
- Jan 31, 2024: Raised $30.0M in Series C
- Dec 30, 2022: Raised $12.2M in Venture - Series Unknown
- Feb 17, 2021: Raised $5.0M in Venture - Series Unknown
- Oct 22, 2020: Raised $6.3M in Venture - Series Unknown
See plans & pricing → Track Halia Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.